Extracellular matrix proteins and blood clot components

Extracellular matrix (ECM) proteins and blood clot components represent a broad category of molecules that provide structural integrity to tissues and facilitate the body's response to vascular injury. The ECM is composed of a complex network of proteins such as collagen, elastin, and fibronectin, which regulate cell adhesion, migration, and signaling through receptors like integrins. Blood clot components, primarily fibrin and platelets, form a provisional matrix at sites of injury to prevent hemorrhage and provide a scaffold for repair. In pathological states, these components are central to the development of arterial and venous thrombosis, chronic organ fibrosis, and the supportive stroma of solid tumors. Therapeutic interventions targeting this group include thrombolytic agents that dissolve fibrin to restore blood flow, anticoagulants that prevent clot expansion, and anti-fibrotic drugs that limit excessive matrix deposition. Additionally, specific molecular signatures within these complexes, such as the fibrin-fibronectin matrix, serve as high-affinity targets for diagnostic imaging and the delivery of targeted therapeutics in oncology and cardiovascular medicine.

Other names

ECM and blood clot componentsThrombus and stroma proteinsFibrin-fibronectin-collagen complexProvisional matrix componentsClotted plasma proteins

Therapeutic agents target these components through several distinct pathways: thrombolytics (e.g., alteplase) act as plasminogen activators to catalyze the degradation of fibrin meshes; anticoagulants (e.g., heparin) inhibit proteases in the coagulation cascade to prevent the conversion of fibrinogen to fibrin; antiplatelet agents (e.g., abciximab) block receptors like glycoprotein IIb/IIIa to prevent platelet aggregation; and anti-fibrotic agents (e.g., nintedanib) inhibit tyrosine kinases or TGF-beta signaling to reduce the synthesis and cross-linking of extracellular matrix proteins such as collagen.